Compare Gilead Sciences, Inc. (GILD) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Petróleo Brasileiro SA — how do they compare? Gilead Sciences, Inc. trades at $135.69 (market cap $163.51B), while Petróleo Brasileiro SA trades at $17.45 (market cap $108.05B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (9.87%). Which is the better fit depends on your goals.
| GILD | PBR | |
|---|---|---|
Market Cap | $163.51B | $108.05B |
Sector | Health | Technology |
52-Week High | $155.80 | $22.03 |
52-Week Low | $108.22 | $11.54 |
Enterprise Value | $178.05B | $170.59B |
Dividend Yield | 2.49% | 9.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Petrobras (PBR) trades at $17.595, down 1.81% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with a P/E of 5.69, robust 21.47% net margin, and consistent dividend payments. Recent developments include strategic acquisitions in Africa and renewable energy investments totaling $1.2 billion. Earnings have shown mixed results, beating expectations in Q3 and Q4 2025 but missing in Q1 2026.
PBR presents an attractive value opportunity with discounted valuation metrics and 50% analyst buy ratings. Upside potential to the $23.90 consensus target offers significant return potential, though risks include oil price volatility and execution challenges in new projects. The company's strong cash flow generation supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
